Is CJC-1295 DAC safe to use during post-cycle therapy without affecting testosterone recovery?

Yes — CJC-1295 DAC acts exclusively through the GHRH receptor and does not interact with the hypothalamic-pituitary-gonadal axis. It stimulates GH release independently of LH, FSH, or testosterone feedback loops, making it one of the few anabolic peptides that can run concurrently with a full PCT protocol without compromising hormonal restoration.

How does CJC-1295 DAC help protect joints after a heavy steroid cycle?

Elevated GH from CJC-1295 DAC stimulates fibroblast collagen synthesis and supports proteoglycan production in articular cartilage — two biosynthetic processes that slow significantly when androgenic support is withdrawn. By maintaining GH output through the bridge phase, athletes address the root cause of post-cycle joint discomfort rather than relying on symptomatic relief alone.

Which peptides are appropriate for a bridge between cycles, and why is CJC-1295 DAC a preferred choice?

Peptides used in a bridge should preserve anabolic signalling without suppressing natural hormone recovery. CJC-1295 DAC qualifies because it amplifies endogenous GH pulses via the GHRH axis, promotes IGF-1-driven nitrogen retention, and carries no androgenic or anti-gonadotropic activity. Its extended half-life also reduces injection burden during the demanding bridge window.

What makes Bluepeps CJC-1295 DAC at 10mg/vial advantageous for experienced users?

At 10 mg per vial, this is the highest single-vial concentration available in the current CJC-1295 product group. Advanced users running higher-dose bridge protocols benefit from fewer vials per cycle, reduced reconstitution frequency, and greater flexibility in tailoring working-solution concentrations to their preferred syringe volume and dosing schedule.

How should Bluepeps CJC-1295 DAC be reconstituted and stored after opening?

Reconstitute with bacteriostatic water by adding solvent slowly against the vial wall to avoid foaming. After reconstitution, store the vial at 2–8 °C (standard refrigerator temperature) and use within the bacteriostatic water's antimicrobial validity window — typically up to four weeks. Protect from light and never freeze the reconstituted solution, as freeze-thaw cycles degrade peptide integrity. (2) angle_used

Batch Tested

Bluepeps

CJC-1295 10mg/vial 1 Vial by Bluepeps

Name: CJC-1295
Brand: Bluepeps
SKU: PEPT-CJC-BLU-003
Price: 48.00 EUR
Availability: InStock

Bluepeps CJC-1295 DAC is a long-acting, albumin-binding growth hormone-releasing hormone analogue supplied as 10 mg of lyophilised peptide per vial, purpose-formulated for athletes who need anabolic support during a post-cycle or bridge window without engaging suppressive pathways. Unlike compounds that interfere with the hypothalamic-pituitary-gonadal axis, CJC-1295 DAC stimulates pulsatile GH release through the GHRH receptor, preserving endogenous testosterone recovery while actively defending lean mass and connective tissue. Batch release at Bluepeps is governed by aseptic fill-finish manufacturing and confirmed through independent analytical verification before any vial reaches dispatch.

€48.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Preserves lean tissue during the androgenic deficit window of PCT
Supports articular cartilage and collagen biosynthesis through GH-driven pathways
Does not suppress LH, FSH, or endogenous testosterone recovery
10 mg per vial provides maximum dosing flexibility for bridge protocols
Extended albumin-bound half-life reduces administration frequency during PCT
Batch Tested by HPLC and LAL assay for sequence accuracy and endotoxin safety
Aseptic fill-finish manufacturing ensures sterility in every vial

Phase	dosage	Note
Bridge (between cycles)	1,000–2,000 mcg per injection, once weekly	Lower end suits first-time bridge users; titrate upward based on GH-response indicators such as sleep quality and joint comfort
PCT support (weeks 1–4)	1,000 mcg per injection, once weekly	Run alongside SERMs; the GHRH axis is independent so no protocol adjustment to SERMs is required
PCT continuation (weeks 5–8)	1,000–1,500 mcg per injection, once weekly	Maintain through full PCT duration to maximise connective tissue recovery and nitrogen retention
Off-season maintenance bridge	500–1,000 mcg per injection, once every 7–10 days	Minimal-dose approach for athletes prioritising joint health over maximum anabolic output

Key takeaways

Use CJC-1295 DAC during PCT to preserve lean mass axis-safely.
Support joint collagen synthesis through GH stimulation post-cycle.
Leverage 10mg/vial concentration for flexible bridge-phase dosing.
Confirm Batch Tested status before every administration.
Combine with SERMs during PCT without risking GH-axis interference.

CJC-1295 DAC as a PCT and Bridge Tool: Keeping Muscle and Joints Intact

Bluepeps CJC-1295 DAC is a synthetic, DAC-modified growth hormone-releasing hormone peptide that selectively amplifies endogenous GH pulses without crossing into the hormonal feedback pathways that post-cycle therapy is designed to restore. That distinction matters enormously between cycles: compounds that blunt LH or FSH recovery cost athletes weeks of hormonal normalisation, whereas CJC-1295 DAC adds an anabolic stimulus through a completely separate neuroendocrine axis. Each vial delivers 10 mg of sequence-verified, lyophilised peptide — the highest single-vial concentration in this product group — giving advanced users flexible dosing headroom across a full bridge protocol.

Lean Tissue Preservation During the Post-Cycle Window

Muscle catabolism accelerates as exogenous androgens clear the system and endogenous testosterone has not yet fully recovered. CJC-1295 DAC counters this by sustaining elevated GH secretion, which in turn drives hepatic IGF-1 production and promotes positive nitrogen retention. Clinical pharmacokinetic data from modified-GRF analogues document an extended serum half-life due to albumin conjugation via the Drug Affinity Complex technology, translating to meaningful GH elevation that persists well beyond a single injection event. Compared to short-acting GHRH fragments requiring daily administration, the DAC modification reduces injection frequency while maintaining consistent anabolic signalling — a practical advantage during the high-compliance demands of PCT.

Joint and Connective Tissue Support After Heavy Cycles

Heavy androgenic cycles frequently leave joints under-recovered: synovial fluid volume drops, collagen turnover slows, and tendons adapt poorly to the rapid loss of androgenic scaffolding. Growth hormone — stimulated by CJC-1295 DAC — directly upregulates collagen synthesis markers in fibroblasts and supports proteoglycan production in articular cartilage, according to peer-reviewed endocrinology literature. CJC-1295 DAC therefore provides joint protection through a mechanism distinct from analgesic peptides: it addresses the underlying biosynthetic deficit rather than masking discomfort. Athletes using CJC-1295 DAC during bridge phases commonly report improved joint comfort within four to six weeks of consistent use.

Batch Tested Quality Assurance

Bluepeps subjects every CJC-1295 DAC lot to reversed-phase HPLC for sequence confirmation and active-content verification, paired with a Limulus Amebocyte Lysate (LAL) endotoxin assay prior to release. Aseptic fill-finish conditions — including ISO-classified cleanroom environments and sterile filtration — ensure that each 10 mg vial meets pharmaceutical-grade sterility standards. Batch-specific test documentation is retained, providing a traceable quality record aligned with GMP principles.

Usage

Calculate your working concentration: dissolve the 10 mg lyophilised peptide in your chosen volume of bacteriostatic water to achieve your target mcg-per-unit dose — for example, 5 mL yields 2 mg/mL.
Allow the vial to reach room temperature before reconstitution to reduce thermal stress on the peptide structure.
Inject the bacteriostatic water gently along the inner wall of the vial; do not force the stream directly onto the lyophilised cake to preserve peptide integrity.
Swirl the vial slowly rather than shaking — vigorous agitation can cause aggregation and reduce potency.
Draw your measured dose into an insulin syringe and administer subcutaneously, rotating injection sites across the bridge or PCT duration to avoid localised tissue irritation.
Log each injection date and dose; because CJC-1295 DAC has a multi-day active window, accurate records prevent unintentional overlap dosing during PCT weeks.

Warnings

Contraindications: Do not use if you have active or suspected malignancy, as GH-stimulating peptides may promote tumour cell proliferation. Individuals with pituitary disorders, untreated hypothyroidism, or known hypersensitivity to GHRH analogues should avoid use. Not intended for use by persons under 18.

Side_Effects: Possible effects include transient water retention, tingling or numbness in the extremities, and mild injection-site reactions. Some users report lethargy during GH-pulse periods, typically occurring at night. Persistent oedema or carpal tunnel-like symptoms warrant dose reduction.

Monitoring: Baseline IGF-1 serum levels measured by immunoassay before starting a bridge protocol allow objective tracking of GH response. Recheck at four weeks. Thyroid function panels (TSH, fT4) are advisable for extended use, as GH elevation can modulate thyroid hormone conversion.

PCT: CJC-1295 DAC does not interfere with SERM activity or endogenous testosterone recovery pathways; it may be run alongside Nolvadex or Clomid without pharmacological conflict. Nonetheless, monitor for additive fluid retention when combining with other compounds that affect aldosterone or cortisol balance during PCT.

Frequently asked questions

Is CJC-1295 DAC safe to use during post-cycle therapy without affecting testosterone recovery?: Yes — CJC-1295 DAC acts exclusively through the GHRH receptor and does not interact with the hypothalamic-pituitary-gonadal axis. It stimulates GH release independently of LH, FSH, or testosterone feedback loops, making it one of the few anabolic peptides that can run concurrently with a full PCT protocol without compromising hormonal restoration.
How does CJC-1295 DAC help protect joints after a heavy steroid cycle?: Elevated GH from CJC-1295 DAC stimulates fibroblast collagen synthesis and supports proteoglycan production in articular cartilage — two biosynthetic processes that slow significantly when androgenic support is withdrawn. By maintaining GH output through the bridge phase, athletes address the root cause of post-cycle joint discomfort rather than relying on symptomatic relief alone.
Which peptides are appropriate for a bridge between cycles, and why is CJC-1295 DAC a preferred choice?: Peptides used in a bridge should preserve anabolic signalling without suppressing natural hormone recovery. CJC-1295 DAC qualifies because it amplifies endogenous GH pulses via the GHRH axis, promotes IGF-1-driven nitrogen retention, and carries no androgenic or anti-gonadotropic activity. Its extended half-life also reduces injection burden during the demanding bridge window.
What makes Bluepeps CJC-1295 DAC at 10mg/vial advantageous for experienced users?: At 10 mg per vial, this is the highest single-vial concentration available in the current CJC-1295 product group. Advanced users running higher-dose bridge protocols benefit from fewer vials per cycle, reduced reconstitution frequency, and greater flexibility in tailoring working-solution concentrations to their preferred syringe volume and dosing schedule.
How should Bluepeps CJC-1295 DAC be reconstituted and stored after opening?: Reconstitute with bacteriostatic water by adding solvent slowly against the vial wall to avoid foaming. After reconstitution, store the vial at 2–8 °C (standard refrigerator temperature) and use within the bacteriostatic water's antimicrobial validity window — typically up to four weeks. Protect from light and never freeze the reconstituted solution, as freeze-thaw cycles degrade peptide integrity. (2) angle_used

Manufacturer

Bluepeps integrates aseptic manufacturing as a non-negotiable production standard, not an optional quality tier. Every CJC-1295 DAC vial is filled under ISO-classified cleanroom conditions with sterile-grade filtration applied prior to lyophilisation, eliminating viable microbial contamination at the point of fill. Incoming peptide raw material and finished vials each undergo distinct analytical checkpoints: reversed-phase HPLC confirms amino-acid sequence integrity and active-content accuracy against the declared 10 mg specification, while an LAL endotoxin assay quantifies residual pyrogenic contamination to ensure compliance with defined safety thresholds. Batch documentation is archived per GMP record-keeping requirements, giving each lot a fully traceable quality identity.

Product details

Brand	Bluepeps
Active ingredient	cjc-1295 with DAC
Also known as	GHRH-Analogon, CJC mit DAC, Bio-Peptide CJC-1295 DAC, CJC-1295, Bluepeps GHRH-Analogon
Strength	10 mg
Form	Vial
Pack size	1 piece
Item number	PEPT-CJC-BLU-003

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Lab Tested

CJC-1295 5mg/vial 1 Vial by Bio-Peptide

CJC-1295 DAC is a Drug Affinity Complex–modified GHRH analogue provided as 5 mg of lyophilized powder per vial, engineered to sustain pulsatile growth hormone stimulation by anchoring to serum albumin — stretching the effective dosing interval from daily to just one or two injections each week. Its extended plasma half-life of roughly 6–8 days positions it as the long-acting member of the CJC-1295 peptide family, distinguishing it clearly from the unmodified Modified GRF 1-29 sequence. Every production batch is subjected to independent HPLC purity analysis and LAL endotoxin quantification before a single unit is approved for release.

€36.00

HPLC Verified

CJC-1295 5mg/vial 1 Vial by Knoll Pharmaceuticals

CJC-1295 DAC from Knoll Pharmaceuticals is supplied as 5 mg of sterile lyophilised powder per vial — a long-acting GHRH analogue engineered for albumin binding that extends its effective half-life well beyond unmodified sequences. Correct reconstitution technique, refrigerated cold-chain storage, and precise subcutaneous injection protocol are each critical to preserving full bioactivity from first use through the final draw. Quality assurance at Knoll Pharmaceuticals covers HPLC identity and purity testing alongside LAL endotoxin quantification, with both checkpoints completed before any vial is cleared for distribution.

€32.00

Top Seller

CJC-DAC 5mg/vial 1 Vial by Master Pharma

Master Pharma CJC-1295 DAC is a lyophilised GHRH analogue delivering 5 mg of high-purity peptide per vial, formulated specifically to pair with Ipamorelin or Mod GRF 1-29 for physiological, pulsatile GH release. The Drug Affinity Complex modification extends circulatory half-life beyond standard Mod GRF 1-29, making it the long-acting backbone of a classic GHRH+GHRP stack. Batch consistency is verified through HPLC purity profiling and LAL endotoxin screening; every vial meets GMP release criteria before distribution.

€35.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00